Description
A potent, selective, orally active S1P receptor-1 (S1P1) agonist with EC50 of 1.1nM, 320-fold selectivity over S1P3; significantly decreases lymphocyte counts at doses of 0.1 and 1mg/kg in rats, demonstrates potential benefits in the treatment of autoimmune diseases. Multiple Sclerosis Phase 3 Clinical